Savaysa (Edoxaban)
edoxaban tosylate monohydrate
Edoxaban Indications
| Indication | Approved Population | Therapy Type | Status |
|---|---|---|---|
| Reduction of stroke and systemic embolism in non-valvular atrial fibrillation (NVAF) | Adults with CrCL >15 to ≤95 mL/min | Monotherapy (anticoagulation) | FDA Approved |
| Treatment of deep vein thrombosis (DVT) | Adults, following 5–10 days of parenteral anticoagulant | Sequential monotherapy | FDA Approved |
| Treatment of pulmonary embolism (PE) | Adults, following 5–10 days of parenteral anticoagulant | Sequential monotherapy | FDA Approved |
Edoxaban is one of four marketed direct oral anticoagulants (DOACs) that inhibit factor Xa. Unlike rivaroxaban and apixaban, edoxaban requires a lead-in period of 5–10 days with a parenteral anticoagulant (typically enoxaparin or unfractionated heparin) before initiating oral therapy for VTE. For NVAF, a critical and unique prescribing consideration is that edoxaban must not be used when CrCL exceeds 95 mL/min because drug levels become subtherapeutic at higher levels of renal clearance, resulting in reduced protection against ischaemic stroke.
VTE prophylaxis following orthopaedic surgery — Edoxaban is approved in Japan for VTE prevention after hip or knee replacement surgery but does not carry this FDA indication. Evidence quality: High (phase III data from STARS trials).
Cancer-associated thrombosis — The Hokusai-VTE Cancer study demonstrated edoxaban was non-inferior to dalteparin for recurrent VTE in cancer patients, although GI bleeding risk was higher in GI malignancies. Evidence quality: High (randomised open-label trial, N = 1,046).
Edoxaban Dosing
Primary Dosing by Clinical Scenario
| Clinical Scenario | Starting Dose | Maintenance Dose | Maximum Dose | Notes |
|---|---|---|---|---|
| NVAF — stroke prevention, CrCL >50 to ≤95 mL/min | 60 mg once daily | 60 mg once daily | 60 mg/day | No titration required; take with or without food Assess CrCL before initiation |
| NVAF — stroke prevention, CrCL 15–50 mL/min | 30 mg once daily | 30 mg once daily | 30 mg/day | Mandatory dose reduction for impaired renal function Do not use if CrCL <15 mL/min |
| DVT/PE treatment — standard risk, CrCL >50 mL/min | 60 mg once daily | 60 mg once daily | 60 mg/day | Must follow 5–10 days of parenteral anticoagulant Duration: 3–12 months per clinical judgement |
| DVT/PE treatment — dose-reduced population | 30 mg once daily | 30 mg once daily | 30 mg/day | Required if any: CrCL 15–50 mL/min, body weight ≤60 kg, or concomitant certain P-gp inhibitors See interactions for P-gp inhibitor list |
| Transition from warfarin to edoxaban | 60 mg once daily | 60 mg once daily | 60 mg/day | Discontinue warfarin; start edoxaban when INR ≤2.5 Apply dose reduction criteria if applicable |
| Transition from edoxaban to warfarin | Overlap protocol — see notes | Option A: Reduce edoxaban dose by 50% (60 mg → 30 mg, or 30 mg → 15 mg), initiate warfarin concurrently; measure INR at least weekly just prior to edoxaban dose to minimise its influence; stop edoxaban once stable INR ≥2.0. Option B: Stop edoxaban, give parenteral anticoagulant and warfarin at the time of the next edoxaban dose, stop parenteral once stable INR ≥2.0 Edoxaban elevates INR — always measure just before the daily edoxaban dose for accuracy (FDA PI) | ||
Edoxaban must not be used for NVAF when CrCL exceeds 95 mL/min. Because approximately 50% of edoxaban is renally cleared, patients with robust kidney function achieve lower drug levels, which the ENGAGE AF-TIMI 48 trial associated with increased ischaemic stroke rates compared to warfarin (FDA PI).
Edoxaban tablets may be crushed and mixed with 2–3 ounces of water or applesauce for patients who cannot swallow whole tablets, or administered via a gastric feeding tube using the same method. This makes edoxaban one of the more flexible DOACs for patients with dysphagia or enteral access (FDA PI).
Pharmacology
Mechanism of Action
Edoxaban is a direct, selective, and reversible inhibitor of free factor Xa (FXa), a serine protease that sits at the convergence point of the intrinsic and extrinsic coagulation pathways. By blocking FXa, edoxaban suppresses the conversion of prothrombin to thrombin, thereby reducing thrombin generation, fibrin clot formation, and thrombin-mediated platelet activation. Unlike indirect FXa inhibitors such as fondaparinux, edoxaban does not require antithrombin III as a cofactor. Peak anti-FXa activity occurs within 1–2 hours of dosing and remains above baseline for approximately 24 hours, supporting once-daily administration. Edoxaban also prolongs clotting tests including prothrombin time and aPTT, although these changes are small, highly variable, and not recommended for therapeutic monitoring.
ADME Profile
| Parameter | Value | Clinical Implication |
|---|---|---|
| Absorption | Oral bioavailability 62%; Tmax 1–2 h; dose-proportional across 15–150 mg | Rapid onset of anticoagulant effect; food does not affect total exposure, allowing flexible dosing relative to meals |
| Distribution | Vdss 107 L; protein binding ~55%; crosses into rat breast milk | Moderate tissue penetration; lower protein binding than apixaban (87%) and rivaroxaban (~90%), meaning haemodialysis does not meaningfully remove edoxaban |
| Metabolism | Primarily hydrolysis via carboxylesterase-1 (CES-1); minor CYP3A4 oxidation and conjugation; active metabolite M-4 (equipotent to parent but exposure <10% of parent) | Minimal CYP involvement reduces conventional CYP-based drug interactions; primary interaction concern is P-glycoprotein efflux transport |
| Elimination | t½ 10–14 h; renal clearance ~50% of total clearance (unchanged drug in urine ~35% of dose); hepatic/biliary ~50%; total clearance ~22 L/h | Dual elimination pathway necessitates dose reduction in renal impairment (CrCL 15–50); steady state reached within 3 days; minimal accumulation (ratio ~1.14) |
Side Effects
| Adverse Effect | Incidence | Clinical Note |
|---|---|---|
| Any bleeding event | 21.7% | Encompasses all bleeding severity levels; most events are clinically relevant non-major bleeding (skin, mucosal) |
| Clinically relevant non-major bleeding | up to 18.1% | Events requiring medical attention but not meeting major bleeding criteria; rate still significantly lower than warfarin |
| Adverse Effect | Incidence | Clinical Note |
|---|---|---|
| Anaemia-related events | 9.6% | Higher than warfarin (6.8%); may reflect occult GI blood loss; monitor haemoglobin periodically |
| Abnormal liver function tests | 4.8% | Comparable to warfarin (4.6%); typically mild transaminase elevations; monitor at baseline and as clinically indicated |
| Rash | 4.2% | Similar rate to warfarin (4.1%); usually non-serious; evaluate for hypersensitivity if accompanied by other systemic symptoms |
| Major bleeding (NVAF setting) | 2.75% | Significantly lower than warfarin (3.43%); NNT 147 over median 2.8 years to prevent one major bleed (ENGAGE AF-TIMI 48) |
| Gastrointestinal bleeding (NVAF setting) | 1.8%/year | Higher than warfarin (1.3%/year); most common site of major bleeds; caution with concurrent antiplatelet therapy or GI malignancy |
| Adverse Effect | Estimated Frequency | Typical Onset | Required Action |
|---|---|---|---|
| Intracranial haemorrhage | 0.5%/year | Any time during therapy | Discontinue immediately; consider andexanet alfa for reversal; emergent neuroimaging and neurosurgical consultation |
| Fatal bleeding | Rare (<0.1%) | Any time during therapy | Immediate resuscitation; activated charcoal if recent ingestion; consider andexanet alfa; supportive haemostatic measures |
| Spinal/epidural haematoma | Very rare (case reports) | Peri-procedural (neuraxial anaesthesia or spinal puncture) | Urgent neurological assessment; surgical decompression if neurological deficit progresses; may result in permanent paralysis |
| Interstitial lung disease | 0.2% | Variable; confounded by concurrent amiodarone in many cases | Discontinue edoxaban; evaluate with chest imaging; 5 fatal cases reported in ENGAGE AF-TIMI 48 (edoxaban arm) |
| Anaphylaxis / angioedema | Very rare (postmarketing) | Any time; often early in therapy | Discontinue permanently; standard anaphylaxis management; switch to alternative anticoagulant |
| Thrombocytopenia | Uncommon (0.1–1%) | Variable | Monitor platelet count; assess for other causes; consider discontinuation if severe or contributing to bleeding |
| Reason for Discontinuation | Incidence | Context |
|---|---|---|
| Bleeding | <4% | Most common reason across both pivotal trials; lower overall rate than warfarin |
| Rash | ~1% | Comparable to warfarin arm; usually resolves after discontinuation |
| Abnormal liver function | <1% | Comparable to warfarin arm; clinically significant hepatotoxicity was not observed |
Edoxaban carries a higher rate of gastrointestinal bleeding than warfarin (1.8% vs 1.3% per year in NVAF). This risk is amplified with concurrent antiplatelet agents, NSAIDs, or in patients with GI malignancy. Consider gastroprotective therapy with a proton pump inhibitor in high-risk patients. Routine stool occult blood testing is reasonable during the first year of therapy. If GI bleeding occurs, ensure haemodynamic stability, hold edoxaban, and consider endoscopic evaluation (ENGAGE AF-TIMI 48).
Drug Interactions
Edoxaban is a substrate of the P-glycoprotein (P-gp) efflux transporter, which is the primary determinant of clinically significant drug interactions. Unlike many other anticoagulants, edoxaban has minimal CYP-mediated metabolism, so conventional CYP inhibitors and inducers are generally not a concern unless they also modulate P-gp. The key interaction principle is straightforward: strong P-gp inhibitors increase edoxaban exposure and may require dose reduction (for VTE only), while strong P-gp inducers decrease edoxaban exposure and should be avoided.
Monitoring
-
Renal Function (CrCL)
Baseline; at least annually; more frequently if unstable
Routine Essential before initiation to determine eligibility (CrCL ≤95 mL/min for NVAF) and dose selection. Re-check if acute illness, dehydration, or nephrotoxic drug added. Use Cockcroft-Gault formula. -
Haemoglobin / Haematocrit
Baseline; then periodically
Routine Monitor for occult bleeding — especially in patients at higher GI bleeding risk. A decline of ≥2 g/dL warrants evaluation for bleeding source. Anaemia-related events occur in ~9.6% of patients. -
Liver Function Tests
Baseline; as clinically indicated
Routine Abnormal LFTs reported in 4.8% of patients. Edoxaban not recommended in moderate-severe hepatic impairment (Child-Pugh B/C) due to intrinsic coagulopathy risk. -
Signs & Symptoms of Bleeding
Every visit
Routine Assess for new bruising, gum bleeding, melaena, haematuria, haemoptysis. Ask about recent falls in elderly patients. Review concurrent antiplatelet or NSAID use at every encounter. -
Stool Occult Blood
As clinically indicated
Trigger-based Consider periodic testing in patients with risk factors for GI bleeding (advanced age, GI malignancy, concurrent antiplatelet therapy). -
Body Weight
Baseline; periodically
Trigger-based Patients with body weight ≤60 kg require dose reduction to 30 mg for DVT/PE treatment. Weight changes may alter drug exposure. -
Anti-Factor Xa Levels
Not routine; only in specific clinical scenarios
Trigger-based Drug-specific calibrated anti-Xa assay may confirm edoxaban presence/absence in emergency situations (overdose, perioperative assessment). Standard PT/INR and aPTT are not reliable for therapeutic monitoring.
Contraindications & Cautions
Absolute Contraindications
- Active pathological bleeding — edoxaban must not be initiated or continued in patients with clinically significant active haemorrhage.
- Hypersensitivity to edoxaban — known allergy to edoxaban or any component of the formulation (angioedema and anaphylaxis reported postmarketing).
Relative Contraindications (Specialist Input Recommended)
- CrCL >95 mL/min (NVAF only) — reduced efficacy compared to warfarin in ENGAGE AF-TIMI 48; another anticoagulant should be used. This restriction does not apply to DVT/PE indications.
- CrCL <15 mL/min — limited clinical data available; edoxaban is not recommended in this population.
- Moderate-to-severe hepatic impairment (Child-Pugh B or C) — these patients may have intrinsic coagulation abnormalities; edoxaban is not recommended.
- Triple-positive antiphospholipid syndrome — DOACs including edoxaban are associated with increased thrombotic risk compared to warfarin in this specific population. Warfarin remains the preferred anticoagulant.
- Mechanical heart valves — no clinical data supporting edoxaban use; warfarin remains the standard of care.
Use with Caution
- Concurrent antiplatelet therapy or chronic NSAID use — substantially increased bleeding risk; weigh the need for dual therapy carefully.
- Elderly patients (>75 years) — higher baseline bleeding risk observed in subgroup analyses of both pivotal trials.
- Low body weight (≤60 kg) — dose reduction applies for DVT/PE treatment; increased drug exposure expected.
- Perioperative setting — discontinue edoxaban at least 24 hours before elective surgery; longer interruption may be needed for procedures with high bleeding risk.
- Patients with GI malignancy — increased GI bleeding risk observed in the Hokusai-VTE Cancer study; carefully weigh benefit against bleed risk.
Edoxaban should not be used in patients with NVAF who have a CrCL greater than 95 mL/min. In the ENGAGE AF-TIMI 48 study, these patients had an increased rate of ischaemic stroke with edoxaban 60 mg compared to warfarin. Another anticoagulant should be selected for these patients. Kidney function must be assessed before initiation.
Stopping edoxaban prematurely in patients with NVAF increases the risk of ischaemic stroke. If anticoagulation with edoxaban must be discontinued for a reason other than pathological bleeding or completion of therapy, cover with another anticoagulant as described in the prescribing information transition guidance.
Epidural or spinal haematomas may occur in patients receiving edoxaban who undergo neuraxial anaesthesia or spinal puncture. These haematomas can result in long-term or permanent paralysis. Risk is increased with indwelling epidural catheters, concurrent use of drugs affecting haemostasis (NSAIDs, platelet inhibitors, other anticoagulants), traumatic or repeated puncture, and a history of spinal deformity or prior spinal surgery. Optimal timing between edoxaban administration and neuraxial procedures has not been established.
Patient Counselling
Purpose of Therapy
Edoxaban is a blood thinner that works by blocking a specific clotting factor (factor Xa) to prevent harmful blood clots. For patients with atrial fibrillation, it reduces the risk of stroke caused by clots forming in the heart. For patients with DVT or PE, it treats existing clots and helps prevent new ones from developing. Unlike warfarin, edoxaban does not require regular blood tests to monitor its level, and it has fewer food and drug interactions.
How to Take
Take one tablet at the same time every day, with or without food. If a dose is missed, take it as soon as remembered on the same day — never take two tablets at once. Always keep an adequate supply and refill the prescription before running out; stopping edoxaban suddenly can increase stroke risk. The tablets can be crushed and mixed with a small amount of water or applesauce if swallowing is difficult.
Sources
- Savaysa (edoxaban) tablets, for oral use. Full Prescribing Information. Daiichi Sankyo, Inc. Revised 2021. DailyMed Primary source for all approved dosing, contraindications, boxed warnings, and adverse reaction incidence data.
- US Food and Drug Administration. NDA 206316 Approval Letter and Label for Savaysa (edoxaban). January 8, 2015. FDA.gov Original FDA approval label with complete clinical pharmacology, pharmacokinetics, and clinical trial data.
- Giugliano RP, Ruff CT, Braunwald E, et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013;369(22):2093-2104. doi:10.1056/NEJMoa1310907 ENGAGE AF-TIMI 48 trial (N = 21,105): pivotal study establishing non-inferiority of edoxaban to warfarin for stroke prevention in NVAF with lower bleeding rates.
- Hokusai-VTE Investigators, Büller HR, Décousus H, et al. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N Engl J Med. 2013;369(15):1406-1415. doi:10.1056/NEJMoa1306638 Hokusai-VTE trial (N = 8,292): established non-inferiority of edoxaban to warfarin for VTE treatment with significantly less clinically relevant bleeding.
- Raskob GE, van Es N, Verhamme P, et al. Edoxaban for the treatment of cancer-associated venous thromboembolism. N Engl J Med. 2018;378(7):615-624. doi:10.1056/NEJMoa1711948 Hokusai-VTE Cancer study (N = 1,046): edoxaban non-inferior to dalteparin for recurrent VTE in cancer; higher GI bleeding in patients with GI tumours.
- January CT, Wann LS, Calkins H, et al. 2019 AHA/ACC/HRS Focused Update of the 2014 Guideline for the management of patients with atrial fibrillation. Circulation. 2019;140(2):e125-e151. doi:10.1161/CIR.0000000000000665 Major US guideline positioning DOACs (including edoxaban) as preferred over warfarin for eligible NVAF patients.
- Steffel J, Collins R, Antz M, et al. 2021 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Europace. 2021;23(10):1612-1676. doi:10.1093/europace/euab065 Comprehensive European clinical practice guide covering DOAC selection, dose adjustment, perioperative management, and switching protocols.
- Kearon C, Akl EA, Ornelas J, et al. Antithrombotic therapy for VTE disease: CHEST Guideline and Expert Panel Report. Chest. 2016;149(2):315-352. doi:10.1016/j.chest.2015.11.026 CHEST guidelines supporting DOACs over warfarin for VTE treatment in non-cancer patients; informs treatment duration decisions.
- Ogata K, Mendell-Harary J, Tachibana M, et al. Clinical safety, tolerability, pharmacokinetics, and pharmacodynamics of the novel factor Xa inhibitor edoxaban in healthy volunteers. J Clin Pharmacol. 2010;50(7):743-753. doi:10.1177/0091270009351883 Early phase I human data establishing the dose-proportional pharmacokinetics and pharmacodynamic profile of edoxaban.
- Parasrampuria DA, Truitt KE. Pharmacokinetics and pharmacodynamics of edoxaban, a non-vitamin K antagonist oral anticoagulant that inhibits clotting factor Xa. Clin Pharmacokinet. 2016;55(6):641-655. doi:10.1007/s40262-015-0342-7 Comprehensive PK review covering absorption, distribution, metabolism, elimination, drug-drug interactions, and special populations.
- Bathala MS, Masumoto H, Oguma T, et al. Pharmacokinetics, biotransformation, and mass balance of edoxaban, a selective, direct factor Xa inhibitor, in humans. Drug Metab Dispos. 2012;40(12):2250-2255. doi:10.1124/dmd.112.046888 Human mass balance study detailing metabolic pathways (CES-1 hydrolysis, minor CYP3A4) and excretion routes.
- Salazar DE, Mendell J, Goss S, et al. Edoxaban in patients with renal impairment: pharmacokinetics and pharmacodynamics. Clin Pharmacol Ther. 2012;91(Suppl 1):S99. doi:10.1038/clpt.2012.19 Data supporting dose reduction in renal impairment; demonstrates exposure increases that plateau with declining CrCL.